Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jürgen Frevert

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Drugs in R&D|August 12, 2010
Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Jürgen Frevert
Toxicon : Official Journal of the International Society on Toxinology|March 19, 2009
Xeomin is free from complexing proteinsJürgen Frevert
Drugs in R&D|January 7, 2015
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A productsJürgen Frevert
Drugs in R&D|April 9, 2015
Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A ProductsJürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|April 1, 2026
Botulinum Toxin: Preclinical and Clinical AspectsDirk Dressler, Jürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2026
Obituary: Hans Bigalke 1946-2024Dirk Dressler, Jürgen Frevert
Biologics : Targets & Therapy|January 7, 2011
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Jürgen Frevert, Dirk Dressler
Journal of Neural Transmission (Vienna, Austria : 1996)|January 27, 2026
Developing Botulinum Toxin Drugs: Unexpected ChallengesDirk Dressler, Jürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|May 5, 2026
Therapeutic botulinum toxin preparations: an updateHans Bigalke, Jürgen Frevert, Dirk Dressler
Toxicology|October 3, 2022
The immunology of botulinum toxin therapy: A brief summaryDirk Dressler, Hans Bigalke, Jürgen Frevert
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Drugs in R&D|August 12, 2010
Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Jürgen Frevert
Toxicon : Official Journal of the International Society on Toxinology|March 19, 2009
Xeomin is free from complexing proteinsJürgen Frevert
Drugs in R&D|January 7, 2015
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A productsJürgen Frevert
Drugs in R&D|April 9, 2015
Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A ProductsJürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|April 1, 2026
Botulinum Toxin: Preclinical and Clinical AspectsDirk Dressler, Jürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2026
Obituary: Hans Bigalke 1946-2024Dirk Dressler, Jürgen Frevert
Biologics : Targets & Therapy|January 7, 2011
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Jürgen Frevert, Dirk Dressler
Journal of Neural Transmission (Vienna, Austria : 1996)|January 27, 2026
Developing Botulinum Toxin Drugs: Unexpected ChallengesDirk Dressler, Jürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|May 5, 2026
Therapeutic botulinum toxin preparations: an updateHans Bigalke, Jürgen Frevert, Dirk Dressler
Toxicology|October 3, 2022
The immunology of botulinum toxin therapy: A brief summaryDirk Dressler, Hans Bigalke, Jürgen Frevert
Pageof 2